Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in Subjects With Advanced Solid Tumors

NCT06076291 is registered in ClinicalTrials.gov with Hangzhou Sumgen Biotech Co., Ltd. as lead sponsor.

NCT NCT06076291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06076291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SG1827 in Subjects With Advanced Solid Tumors
Lead sponsor
Hangzhou Sumgen Biotech Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 27, 2023
Completion date
March 18, 2026
Enrollment
19 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors